CLDF Title
Home | Contact Us | Bookmark
    HCC   HE   HRS   NASH   PBC   THROMBOCYTOPENIA  
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Drug for alpha-1 antitrypsin deficiency fails key trial

Drug for alpha-1 antitrypsin deficiency fails key trial

By Reuters Staff

(Reuters) - Israel-based drugmaker Kamada Ltd said its experimental drug failed in a key trial to treat an inherited condition that raises the risk of lung and liver disease.

The hereditary disorder, called Alpha-1 Antitrypsin deficiency, is characterized by low levels of the protein alpha-1 antitrypsin found in the blood.

The deficiency predisposes individuals to several conditions, including lung, liver disease and sometimes panniculitis - a skin condition.

The trial was testing the inhaled drug, AAT, against a placebo in 168 patients with the disorder.

Early data showed the treatment was not more effective than the placebo.

The company said it planned to release detailed results of the study in the third quarter.

Kamada is also evaluating the treatment for use in cystic fibrosis, bronchiectasis and diabetes.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.